Prasugrel in the management of acute coronary syndromes: a systematic review.
DaruSep 17, 2026 (epub)
Canan Akman, Asli Bahar Ucar, Mehmet Unaldi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluates the use of prasugrel in acute coronary syndromes (ACS), highlighting its pharmacological advantages over clopidogrel and ticagrelor. The review synthesizes evidence from various studies, concluding that prasugrel significantly reduces ischaemic events in ACS patients undergoing percutaneous coronary intervention. Patient selection is crucial due to contraindications such as prior stroke.
Key findings
- Prasugrel reduces ischaemic events compared to clopidogrel in ACS patients undergoing intervention.
- Prasugrel demonstrated superiority over ticagrelor in major trials.
- Patient selection is critical, with contraindications including prior stroke and active bleeding.
Why it matters
Understanding the efficacy and safety profile of prasugrel is essential for clinicians managing ACS, as it informs treatment decisions and patient selection, ultimately impacting patient outcomes.